perceived pack of patentability but are made to clarify the wording of the claim (claims 31 and 33), or to direct a claim to a particularly important embodiment (claims 32 and 34).

New claims 35-64 are supported in the specification, at least at pages 27-33.

Conclusion

Applicant requests examination of claims 31-64. If there is any minor matter preventing examination of those claims, applicant requests that Examiner Chen contact the undersigned attorney.

It is believed that no fee is required for this Amendment and Reply. However, if there are unanticipated fees required to maintain the pendency of this application, the PTO is authorized to withdraw those fees from Deposit Account 01-1785. Overcharges may also be credited to Deposit Account 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: New York, New York
December 4, 2002

By: _____
Elie H. Gendloff
Registration No.: 44,704

Appendix - Marked-Up Claims Pending After Amendment
U.S. Patent Application 10/035,914
Additions are underlined and deletions are bracketed

31. (Amended) A method for determining whether a subject has an astrocytoma, the method comprising assaying for CD81 expression in a diagnostic sample of cells of astrocytic lineage of the subject, wherein no detection of expression of CD81 in cells of astrocytic lineage of the subject is diagnostic of an astrocytoma.

32. (Amended) The method of [C]claim 31, wherein the diagnostic sample of cells of astrocytic lineage of the subject is assayed *in vitro* [or *in vivo*].

33. (Amended) A method for assessing the efficacy of astrocytoma therapy in a subject who has undergone or is undergoing treatment for an astrocytoma, the method comprising assaying for CD81 expression in a diagnostic sample of cells of astrocytic tumor cells of the subject, wherein no detection of expression of CD81 in astrocytic tumor cells of the subject is indicative of unsuccessful astrocytoma therapy.

34. (Amended) The method of claim 33, wherein the diagnostic sample of cells of astrocytic lineage of the subject is assayed *in vitro* [or *in vivo*].

35. (New) The method of claim 31, wherein the subject is a mammal.

36. (New) The method of claim 31, wherein the subject is a human.

37. (New) The method of claim 31, wherein CD81 expression is assayed using an immunological technique.

38. (New) The method of claim 37, wherein the immunological technique utilizes an antibody, an Fab fragment, or an $F(ab')_2$ fragment.

39. (New) The method of claim 38, wherein the antibody, Fab fragment, or $F(ab')_2$ fragment is monoclonal.

40. (New) The method of claim 38, wherein the antibody, Fab fragment, or $F(ab')_2$ fragment is polyclonal.

41. (New) The method of claim 38, wherein the antibody, Fab fragment, or $F(ab')_2$ fragment is labeled with a detectable marker.

42. (New) The method of claim 41, wherein the detectable marker is a nonradioactive or a fluorescent marker.

43. (New) The method of claim 41, wherein the detectable marker is a radioactive marker.

44. (New) The method of claim 31, wherein CD81 expression is assayed using hybridization analysis.

45. (New) The method of claim 44, wherein the hybridization analysis is a northern blot analysis for CD81 mRNA in mRNA extracted from cells of astrocytic lineage.

46. (New) The method of claim 44, wherein the hybridization analysis utilizes an RNA probe.

47. (New) The method of claim 44, wherein the hybridization analysis utilizes a DNA probe.

48. (New) The method of claim 32, wherein CD81 expression is assayed using RT-PCR.

49. (New) The method of claim 31, wherein CD81 expression is assayed using fluorescence imaging techniques.

50. (New) The method of claim 31, wherein CD81 expression is assayed using radiation detection.

51. (New) The method of claim 32, wherein CD81 expression is assayed using immunocytofluorometry.

52. (New) The method of claim 33, wherein the subject is a human.

53. (New) The method of claim 33, wherein CD81 expression is assayed using an immunological technique.

54. (New) The method of claim 53, wherein the immunological technique utilizes an antibody, an Fab fragment, or an $F(ab')_2$ fragment.

55. (New) The method of claim 54, wherein the antibody, Fab fragment, or $F(ab')_2$ fragment is monoclonal.

56. (New) The method of claim 54, wherein the antibody, Fab fragment, or $F(ab')_2$ fragment is labeled with a detectable marker.

57. (New) The method of claim 33, wherein CD81 expression is assayed using hybridization analysis.

58. (New) The method of claim 57, wherein the hybridization analysis is a northern blot analysis for CD81 mRNA in mRNA extracted from cells of astrocytic lineage.

59. (New) The method of claim 57, wherein the hybridization analysis utilizes an RNA probe.

60. (New) The method of claim 57, wherein the hybridization analysis utilizes a DNA probe.

61. (New) The method of claim 34, wherein CD81 expression is assayed using RT-PCR.

62. (New) The method of claim 33, wherein CD81 expression is assayed using fluorescence imaging techniques.

63. (New) The method of claim 33, wherein CD81 expression is assayed using radiation detection.

64. (New) The method of claim 34, wherein CD81 expression is assayed using immunocytofluorometry.